Improved understanding of interactions in ASDs: the case of Lumefantrine-Soluplus® produced by Vertical HME
Fan Yang – Research Intern, Institut Jean Lamour - Université de Lorraine CNRS; Ghouti Medjahdi – Research Engineer, Institut jean Lamour - CNRS-Université de Lorraine; Pascal Boulet – Research Engineer, Institut Jean Lamour - Université de Lorraine-CNRS; Victoire de Margerie – Executive Chairman, Rondol Industrie
Director Global Business Development and Operations Rondol Industrie Nancy, Lorraine, France
Introduction: Lumefantrine (LUM) is a poorly soluble, fed-state dependent pediatric antimalarial treatment recommended by the World Health Organisation.This project focuses on developing child- friendly formulations that combine Lumefantrine and Soluplus®(SOL) while using vertical hot melt extrusion (VHME) in order to produce amorphous solid dispersions (ASDs) with improved bioavailability. Understanding LUM–Soluplus® interactions is essential to predict ASD behaviors, including drug conservation and stability under hot and humid conditions.
Learning Objectives:
Interpret solid-state characterization techniques to assess nanoscale organization and stability of formulation
How API–polymer interactions influence molecular dispersion, physical stability, and recrystallization.
Understand the role of vertical hot-melt extrusion (VHME) in the development of ASDs for poorly soluble drugs.
